Dabur's business update for Q3FY26 indicated mid-single digit consolidated revenue growth. The guidance is that growth in operating and net profits will beat revenue growth. In the domestic business, home and personal care (HPC) revenue grew in double digits, while healthcare is likely to post a sequential growth in low-single digits.
Fast-moving consumer goods (FMCG) companies like Dabur India and Marico anticipate high single-digit growth in Q4FY26, driven by strong domestic demand in India, which is helping to offset the negative impact of geopolitical conflicts in West Asia on their international businesses.
Home-grown FMCG major Dabur India on Thursday said it will set up a Rs 400-crore manufacturing plant in Tamil Nadu's Villupuram district, marking the company's maiden foray into the South. State Industries Minister TRB Rajaa said, Dabur has signed a Memorandum of Understanding (MoU) with the state government to this effect on Thursday. The MoU outlines an approved Phase 1 investment of Rs 135 crore, scaling up to Rs 400 crore over five years, Dabur India said in a statement.
After being cornered by Patanjali and macro-headwinds, ayurveda major Dabur is pulling up its socks. With better sales and improved margins, the firm is now looking to leverage the renewed popularity of ayurveda, mostly ignited by rival Patanjali. Sunil Duggal, bottom, left, chief executive officer, Dabur India, shares his plans and insights with Arnab Dutta.
Dabur has moved quickly to take advantage of the ban.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances